This HTML5 document contains 84 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00609/identifier/national-drug-code-directory/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/drugbank/company/
n9http://linked.opendata.cz/resource/mesh/concept/
n28http://linked.opendata.cz/resource/drugbank/dosage/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00609/identifier/chemspider/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00609/identifier/chebi/
n16http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00609/identifier/pharmgkb/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00609/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n26http://linked.opendata.cz/resource/drugbank/drug/DB00609/identifier/kegg-compound/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00609/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/resource/drugbank/medicinal-product/
n8http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n12http://www.drugs.com/cdi/
n18http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00609/identifier/kegg-drug/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00609/identifier/pubchem-substance/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00609/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00609
rdf:type
n3:Drug
n3:description
A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)
n3:dosage
n28:271B55A5-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
2 to 3 hours
n3:indication
For use in the treatment of pulmonary and extrapulmonary tuberculosis when other antitubercular drugs have failed.
n3:manufacturer
n13:271B55A2-363D-11E5-9242-09173F13E4C5
owl:sameAs
n16:DB00609 n17:DB00609
dcterms:title
Ethionamide
adms:identifier
n6:46506077 n7:2761171 n19:PA164768738 n20:Ethionamide n23:D00591 n24:0008-4117-01 n25:DB00609 n26:C07665 n27:4885 n29:2041901
n3:mechanismOfAction
Ethionamide may be bacteriostatic or bactericidal in action, depending on the concentration of the drug attained at the site of infection and the susceptibility of the infecting organism. Ethionamide, like prothionamide and pyrazinamide, is a nicotinic acid derivative related to isoniazid. It is thought that ethionamide undergoes intracellular modification and acts in a similar fashion to isoniazid. Isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall. Specifically isoniazid inhibits InhA, the enoyl reductase from <i>Mycobacterium tuberculosis</i>, by forming a covalent adduct with the NAD cofactor. It is the INH-NAD adduct that acts as a slow, tight-binding competitive inhibitor of InhA.
n3:packager
n13:271B55A1-363D-11E5-9242-09173F13E4C5 n13:271B55A0-363D-11E5-9242-09173F13E4C5 n13:271B559F-363D-11E5-9242-09173F13E4C5 n13:271B559E-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Less than 1% of the oral dose is excreted as ethionamide in urine. Ethionamide is extensively metabolized to active and inactive metabolites.
n3:synonym
Etioniamid Ethinamide Ethyonomide ETP ETH Etionamide Etionamida 2-ethylthioisonicotinamide Ethionamide Ethioniamide Trecator Ethionamidum Etionamid 2-Ethyl-4-thiopyridylamide Ethylisothiamide
n3:toxicity
Symptoms of overdose include convulsions, nausea, and vomiting.
n3:volumeOfDistribution
* 93.5 L [healthy volunteers]
n3:proteinBinding
Approximately 30% bound to proteins.
n3:synthesisReference
Chimie et Atomistique, France: British Patent 800,250: August 20, 1958.
n8:hasConcept
n9:M0007869
foaf:page
n12:ethionamide.html n18:ethionamide.htm
n3:IUPAC-Name
n4:271B55AA-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B55B0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B55AF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B55AC-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B55AD-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B55AE-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B55C0-363D-11E5-9242-09173F13E4C5 n4:271B55A8-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B55C2-363D-11E5-9242-09173F13E4C5 n4:271B55A6-363D-11E5-9242-09173F13E4C5 n4:271B55A9-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B55A7-363D-11E5-9242-09173F13E4C5
n21:hasATCCode
n22:J04AD03
n3:H-Bond-Acceptor-Count
n4:271B55B6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B55B7-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B55B1-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B55B2-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B55B4-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B55B3-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B55B5-363D-11E5-9242-09173F13E4C5
n3:absorption
Essentially completely absorbed following oral administration and not subjected to any appreciable first pass metabolism. Bioavailability approximately 100%.
n3:affectedOrganism
Mycobacteria
n3:casRegistryNumber
536-33-4
n3:category
n3:containedIn
n14:271B55A3-363D-11E5-9242-09173F13E4C5 n14:271B55A4-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B55BC-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B55BE-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B55BF-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B55C1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B55BB-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B55BA-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B55BD-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B55AB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B55B8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B55B9-363D-11E5-9242-09173F13E4C5